Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review (Q89666569)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

7 April 2020

review article

1 reference

title

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

7 April 2020

main subject

irritable bowel syndrome

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

7 April 2020

author name string

Eric D Shah

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

7 April 2020

Herbert L DuPont

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

7 April 2020

publication date

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

Therapeutic Advances in Gastroenterology

7 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

7 April 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

7 April 2020

page(s)

1756284819897531

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

7 April 2020

cites work

1 reference

12 December 2020

Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients

1 reference

12 December 2020

In vitro activity and fecal concentration of rifaximin after oral administration

1 reference

12 December 2020

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

1 reference

12 December 2020

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

1 reference

12 December 2020

Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome

1 reference

12 December 2020

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic

1 reference

12 December 2020

Postinfectious irritable bowel syndrome may occur after non-gastrointestinal and intestinal infection

1 reference

12 December 2020

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

1 reference

12 December 2020

Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen

1 reference

12 December 2020

Irritable bowel syndrome in persons who acquired trichinellosis

1 reference

12 December 2020

Rifaximin is a gut-specific human pregnane X receptor activator

1 reference

12 December 2020

A new rat model links two contemporary theories in irritable bowel syndrome

1 reference

12 December 2020

Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.

1 reference

12 December 2020

Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora

1 reference

12 December 2020

Pathogen recognition and inflammatory signaling in innate immune defenses

1 reference

12 December 2020

Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei

1 reference

12 December 2020

Bile acids improve the antimicrobial effect of rifaximin

1 reference

12 December 2020

Differential expression of toll-like receptors in patients with irritable bowel syndrome.

1 reference

12 December 2020

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

1 reference

12 December 2020

Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review

1 reference

12 December 2020

Acute and Chronic Histological Changes of the Small Bowel Secondary to C. jejuni Infection in a Rat Model for Post-Infectious IBS

1 reference

12 December 2020

Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells

1 reference

12 December 2020

Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells

1 reference

12 December 2020

The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

1 reference

12 December 2020

The biology of the cytolethal distending toxins

1 reference

12 December 2020

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis

1 reference

12 December 2020

Evaluation of harm in the pharmacotherapy of irritable bowel syndrome

1 reference

12 December 2020

Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak

1 reference

12 December 2020

Role of Cytolethal Distending Toxin in Altered Stool Form and Bowel Phenotypes in a Rat Model of Post-infectious Irritable Bowel Syndrome

1 reference

12 December 2020

Effect of repeated Campylobacter jejuni infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes

1 reference

12 December 2020

Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.

1 reference

12 December 2020

Sensitivity testing in irritable bowel syndrome with rectal capsaicin stimulations: role of TRPV1 upregulation and sensitization in visceral hypersensitivity?

1 reference

12 December 2020

Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood

1 reference

12 December 2020

Antibiotic treatment of constipation-predominant irritable bowel syndrome

1 reference

12 December 2020

Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis

1 reference

12 December 2020

Susceptibility to Campylobacter infection is associated with the species composition of the human fecal microbiota

1 reference

12 December 2020

The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome: a population-based case-control study

1 reference

12 December 2020

Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model

1 reference

12 December 2020

Characterization of the human gut microbiome during travelers' diarrhea

1 reference

12 December 2020

Irritable bowel syndrome: a clinical review.

1 reference

12 December 2020

Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers' diarrhoea

1 reference

12 December 2020

Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates

1 reference

12 December 2020

Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders

1 reference

12 December 2020

Composition of human faecal microbiota in resistance to Campylobacter infection.

1 reference

12 December 2020

Microbial signatures in post-infectious irritable bowel syndrome--toward patient stratification for improved diagnostics and treatment

1 reference

12 December 2020

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach

1 reference

12 December 2020

A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review

1 reference

12 December 2020

Serum immune biomarkers in irritable bowel syndrome

1 reference

12 December 2020

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome

1 reference

12 December 2020

Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB Pathway

1 reference

12 December 2020

Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome

1 reference

12 December 2020

Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome

1 reference

12 December 2020

Revised Estimates for the Number of Human and Bacteria Cells in the Body

1 reference

12 December 2020

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.

1 reference

12 December 2020

Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome

1 reference

12 December 2020

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin

1 reference

12 December 2020

Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis

1 reference

12 December 2020

Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth

1 reference

12 December 2020

Epithelial expression and function of trypsin-3 in irritable bowel syndrome

1 reference

12 December 2020

Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis

1 reference

12 December 2020

Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy

1 reference

12 December 2020

Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus

1 reference

12 December 2020

Transient receptor potential ion channel function in sensory transduction and cellular signaling cascades underlying visceral hypersensitivity

1 reference

12 December 2020

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

1 reference

12 December 2020

VIP and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.

1 reference

12 December 2020

Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels

1 reference

12 December 2020

Are characteristics of abdominal pain helpful to identify patients with visceral hypersensitivity in irritable bowel syndrome? Results of a prospective study.

1 reference

12 December 2020

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome

1 reference

12 December 2020

Cytokine Profile and Immunoglobulin E-mediated Serological Food Hypersensitivity in Patients With Irritable Bowel Syndrome With Diarrhea.

1 reference

12 December 2020

Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis

1 reference

12 December 2020

Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome

1 reference

12 December 2020

Characteristics of the bacterial microbiome in association with common intestinal parasites in irritable bowel syndrome.

1 reference

12 December 2020

American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

1 reference

12 December 2020

Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome

1 reference

12 December 2020

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome

1 reference

12 December 2020

Relationships of Microbiome Markers With Extraintestinal, Psychological Distress and Gastrointestinal Symptoms, and Quality of Life in Women With Irritable Bowel Syndrome

1 reference

12 December 2020

Long-Term Gastrointestinal Consequences are Frequent Following Sporadic Acute Infectious Diarrhea in a Tropical Country: A Prospective Cohort Study

1 reference

12 December 2020

Antibiotics: a risk factor for irritable bowel syndrome in a population-based cohort

1 reference

12 December 2020

Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation

1 reference

12 December 2020

Expression of Toll-like Receptors, Pro-, and Anti-inflammatory Cytokines in Relation to Gut Microbiota in Irritable Bowel Syndrome: The Evidence for Its Micro-organic Basis

1 reference

12 December 2020

Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756284819897531

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

7 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32047534 AND SRC:MED&resulttype=core&format=json

7 April 2020

PubMed publication ID

32047534

1 reference